StockData
Evaxion A/S logo

Evaxion A/S (EVAX) stock

EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$2.78+0.01 (+0.36%)

Close on Nov 17, 2026Market cap $23.19MP/E –Yield –

Evaxion A/S r&d expenses

Research and development expenses are spending on new products and technology.

Evaxion A/S's R&D Expenses for the twelve months ending Jun 30, 2022 was $19.49M, up 31.4% year over year. For fiscal 2025 it was $9.98M, down 4.6% from the year before. The highest annual figure on record is $19.58M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.98M-4.6%
FY2024Dec 31, 2024$10.46M-12.2%
FY2023Dec 31, 2023$11.92M-30.1%
FY2022Dec 31, 2022$17.06M-12.9%
FY2021Dec 31, 2021$19.58M+79.6%
FY2020Dec 31, 2020$10.90M+32.7%
FY2019Dec 31, 2019$8.22M+120.3%
FY2018Dec 31, 2018$3.73M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.33M-43.2%
Q2 FY2025Jun 30, 2025$2.17M-54.9%
Q2 FY2024Jun 30, 2024$2.75M-55.3%
Q2 FY2023Jun 30, 2023$2.94M-33.5%
Q2 FY2022Jun 30, 2022$4.11M-19.5%
Q1 FY2022Mar 31, 2022$4.80M+23.4%
Q4 FY2021Dec 31, 2021$6.15M+115.5%
Q3 FY2021Sep 30, 2021$4.42M+48.9%
Q2 FY2021Jun 30, 2021$5.11M+98.9%
Q1 FY2021Mar 31, 2021$3.89M+55.1%
Q4 FY2020Dec 31, 2020$2.86M–
Q3 FY2020Sep 30, 2020$2.97M–
Q2 FY2020Jun 30, 2020$2.57M–
Q1 FY2020Mar 31, 2020$2.51M–

More Evaxion A/S figures

See a number that looks wrong?